登录 | 注册    关注公众号  
微信公众号
搜索
 > 【Fusion glycoprotein F0】

Fusion glycoprotein F0信息

英文名称:Respiratory syncytial virus F protein
中文名称:呼吸道合胞病毒F蛋白
靶点别称
上市药物数量:2
临床药物数量:5
最高研发阶段:批准上市

Fusion glycoprotein F0分子别名

Fusion glycoprotein F0

Fusion glycoprotein F0分子背景

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation. Antibody 101F, target epitopes that have been mapped to linear regions in the F1 subunit, referred to as antigenic site IV.

Fusion glycoprotein F0上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验

Fusion glycoprotein F0临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定